1. |
Imboden JB. The immunopathogenesis of rheumatoid arthritis[J]. Annu Rev Pathol, 2009, 4: 417-434.
|
2. |
Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 cells[J]. Annu Rev Immunol, 2009, 27: 485-517.
|
3. |
Nakae S, Nambu A, Sudo K, et al. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice[J]. J Immunol, 2003, 171(11): 6173-6177.
|
4. |
Lubberts E, Koenders MI, Oppers-Walgreen B, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion[J]. Arthritis Rheum, 2004, 50(2): 650-659.
|
5. |
Sarkar S, Fox DA. Targeting IL-17 and Th17 cells in rheumatoid arthritis[J]. Rheum Dis Clin North Am, 2010, 36(2): 345-366.
|
6. |
Melis L, Vandooren B, Kruithof E, et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis[J]. Ann Rheum Dis, 2010, 69(3): 618-623.
|
7. |
Hitchon CA, Alex P, Erdile LB, et al. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis[J]. J Rheumatol, 2004, 31(12): 2336-2346.
|
8. |
Mika K, Akito T, Hiroto M, et al. Interleukin-17 gene expression in patients with rheumatoid arthritis[J]. Mod Rheumatol, 2008, 18(1): 15-22.
|
9. |
Yamada H, Nakashima Y, Okazaki K, et al. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis[J]. Ann Rheum Dis, 2008, 67(9): 1299-1304.
|
10. |
Cho ML, Yoon CH, Hwang SY, et al. Effector function of typeⅡ collagen-stimulated T cells from rheumatoid arthritis patients: cross-talk between T cells and synovial fibroblasts[J]. Arthritis Rheum, 2004, 50(3): 776-784.
|
11. |
Zhu JF, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations[J]. Annu Rev Immunol, 2010, 28: 445-489.
|
12. |
卢月, 曹雅晶, 钱瑞琴. IL-17在类风湿关节炎发病机制中的作用[J]. 中国免疫学杂志, 2011, 27(9): 855-859.
|
13. |
Hwang SY, Kim JY, Kim KW, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways[J]. Arthritis Res Ther, 2004, 6(2): 120-128.
|
14. |
Moran EM, Connolly M, Gao W, et al. Interleukin-17a induction of angiogenesis, cell migration, and cytoskeletal rearrangement[J]. Arthritis Rheum, 2011, 63(11): 3263-3273.
|
15. |
Shahrara S, Pickens SR, Mandelin AM, et al. IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction[J]. J Immunol, 2010, 184(8): 4479-4487.
|
16. |
Van HJ, Asmawidjaja PS, Davelaar N, et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction,including autocrine interleukin-17A production[J]. Arthritis Rheum, 2011, 63(1): 73-83.
|
17. |
Pöllinger B, Junt T, Metzler B, et al. Th17 cells, not IL-17+γδ T cells, drive arthritic bone destruction in mice and humans[J]. J Immunol, 2011, 186(4): 2602-2612.
|
18. |
Braun T, Zwerina J. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis[J]. Arthritis Res Ther, 2011, 13(4): 235.
|
19. |
Mitsdoerffer M, Lee Y, Jäger A, et al. Proinflammatory T helper type 17 cells are effective B-cell helpers[J]. Proc Natl Acad Sci USA, 2010, 107(32): 14292-14297.
|
20. |
Eklund CM. Proinflammatory cytokines in CRP baseline regulation[J]. Adv Clin Chem, 2009, 48: 111-136.
|